Summary & Overview
CPT 86826: HLA Crossmatch by Flow Cytometry or Other Non-Cytotoxic Method
CPT code 86826 denotes an HLA crossmatch test performed after the initial specimen, evaluating donor lymphocytes against a recipient serum or dilution using non-cytotoxic methods such as flow cytometry. This assay is a critical component of pre-transplant immunologic assessment and antibody detection, informing donor-recipient compatibility and transplant risk stratification across transplant centers nationally. The code matters for clinical laboratories and transplant programs because it documents a specialized immunogenetics service with implications for patient management and billing clarity.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical purpose of 86826, typical sites of service, and how the service fits into transplant and transfusion workflows. The publication provides benchmarks and payor coverage context where available, notes common modifiers and billing considerations, and highlights the clinical context of flow cytometry-based crossmatching versus cytotoxic methods. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 86826 describes a laboratory HLA crossmatch test performed by a lab analyst comparing donor lymphocytes with a recipient serum sample or dilution subsequent to the initial specimen. The assay evaluates human leukocyte antigen (HLA) compatibility using non-cytotoxic methods, for example flow cytometry, to detect antibody-mediated reactivity between donor cells and recipient serum.
Service type: Immunogenetics / HLA compatibility testing
Typical site of service: Clinical laboratory (specialty immunology or transfusion medicine laboratory) or hospital laboratory performing pre-transplant compatibility testing.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45-year-old individual awaiting allogeneic hematopoietic stem cell transplantation for aplastic anemia. Pre-transplant compatibility testing is ordered by the transplant team. The clinical workflow begins when the donor and recipient blood specimens are collected in the transfusion/lab draw unit. The immunogenetics laboratory receives the recipient serum and donor lymphocyte sample. A laboratory analyst performs an HLA crossmatch using a non-cytotoxic method such as flow cytometry to detect anti-donor antibodies bound to donor lymphocytes. Results are reviewed by the immunogenetics supervisor and reported to the transplant physician and blood bank. If a positive crossmatch is identified, the transplant team and blood bank document incompatibility and consider alternate donor selection or desensitization protocols. If negative, compatibility is documented and used to proceed with transplant planning and final blood product selection. The typical site of service is an accredited hospital immunology/transfusion laboratory or reference immunogenetics laboratory supporting inpatient and outpatient transplant programs.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier; standard procedure code | Use when no additional billing modifier applies |
11 |